Study of ABSK043 and Firmonertinib for EGFR-mutant lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new combination of two targeted therapies (ABSK043 and firmonertinib) for people with a specific type of advanced lung cancer. It is for patients whose tumors have an EGFR mutation and are PD-L1 positive.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer that cannot be removed by surgery or has spread.
- Your tumor has a specific EGFR mutation (L858R or exon 19 deletion) shown in a gene test.
- Your cancer has at least one tumor that can be measured on scans.
- Your tumor is PD-L1 positive (at least 1% of cells express PD-L1).
- For some groups: you have either never had treatment for advanced lung cancer, OR your cancer grew after an EGFR inhibitor.
- You do not have severe organ problems, active brain metastasis, or a history of lung inflammation (interstitial lung disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral targeted therapy (firmonertinib) as the first treatment for advanced EGFR-mutated non-small cell lung cancer. It uses blood tests (ctDNA) to see if the drug is working and to guide whether to continue or adjust treatment, aiming to improve outcomes while reducing side effects.
This trial tests a combination of two experimental drugs, ABSK043 and Glecirasib, for people with a specific type of advanced non-small cell lung cancer (NSCLC). The goal is to see if the combination works better than standard treatments.
This trial tests a new targeted pill (Firmonertinib) combined with standard chemotherapy for stage III lung cancer that cannot be removed by surgery. It is for people with a specific EGFR mutation, and the goal is to see if the combo helps shrink or control the cancer.
This trial tests a new pill called firmonertinib against standard EGFR inhibitor pills for people with advanced non-small cell lung cancer that has certain uncommon EGFR mutations. It aims to see if firmonertinib works better in stopping the cancer from growing.
This trial tests whether combining the targeted pill firmonertinib with radiation therapy can help people with stage III non-small cell lung cancer that has certain rare EGFR mutations. It is for those whose cancer cannot be removed by surgery.
This trial tests a targeted therapy pill (firmonertinib) given before and after surgery for stage II–III lung adenocarcinoma that has an EGFR mutation. The goal is to see if this approach can shrink the tumor before surgery and reduce the chance of cancer coming back.
Hear when a new Non-Small Cell Lung Cancer With EGFR Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.